Glenmark Pharmaceuticals Limited is a Pharmaceuticals company listed on the National Stock Exchange (NSE) with a market capitalisation of ₹74,507 crore. The company reports ROE of 14%, a net profit margin of 9.1%. Revenue grew -29.8% year-over-year. Promoter holding stands at 49%, with FII participation at 27.5%.
Price is rising consistently (EMA alignment — short and medium-term averages both pointing up). Buying pressure is building (RSI/MACD momentum confirmed). Trading near its strongest price of the year (within 5% of 52-week high). A trend-following indicator is on the bullish side (SuperTrend signal: buy). The uptrend is visible even on the weekly chart (longer-term trend confirmed). Short-term oscillator is overheated — entering now means chasing (StochRSI above 80, late entry risk). Both short and medium-term trend lines are pointing upward — the trend has momentum (rising EMA20 + EMA50). Price is right at the ceiling of this year's range — a close above would be a significant breakout (at 52W high zone). Foreign institutions have been net buyers for 3 consecutive days — sustained institutional demand (✅ FII buying streak).
Glenmark Pharmaceuticals Limited scores 60/100 (Positive Research Signal). The strongest signals are Trend (17/100) and Momentum (13/100). The weakest dimension is Growth (0/100), which warrants monitoring. This reflects JaySense quantitative research scoring only — not investment advice. Consult a SEBI Registered Investment Adviser before making any investment decision.
| Stock | Score | Signal |
|---|---|---|
|
SUNPHARMA
Sun Pharmaceutical Industries Limited
|
84 | High Conviction |
|
AUROPHARMA
Aurobindo Pharma Limited
|
75 | High Conviction |
|
APOLLOHOSP
Apollo Hospitals Enterprise Limited
|
73 | High Conviction |
|
DIVISLAB
Divi's Laboratories Limited
|
72 | High Conviction |
|
CIPLA
Cipla Limited
|
69 | Positive Setup |